Real-world biologics response and super-response in the International Severe Asthma Registry cohort.
Eve J DentonMark HewMatthew J PetersJohn W UphamLakmini BulathsinhalaTrung N TranNeil MartinCeline BergeronMona Al AhmadAlan AltrajaDésirée Erlinda Larenas-LinnemannRuth MurrayCarlos Andrés Celis-PreciadoRiyad Al-LehebiManon BelhassenMohit BhutaniSinthia Z Bosnic-AnticevichArnaud BourdinGuy G O BrusselleJohn BusbyGiorgio Walter CanonicaEnrico HefflerKenneth R ChapmanJérémy CharriotGeorge C ChristoffLi Ping ChungBorja García CosioAndréanne CôtéRichard W CostelloBreda CushenJames FingletonJoão Almeida FonsecaPeter Gerard GibsonLiam G HeaneyErick Wan-Chun HuangTakashi IwanagaAlexandra M NanzerMariko Siyue KohLauri A LehtimäkiJorge F MasperoBassam MahboubAndrew N Menzies-GowPatrick D MitchellPapadopoulos G NikolaosAndriana I PapaioannouLuis A Perez-de-LlanoDiahn-Warng PerngPaul E PfefferTodor A PopovCeleste M PorsbjergChin Kook RheeNicholas RocheJ Mark FitzGeraldSundeep SalviJohannes Martin SchmidChau-Chyun SheuConcetta SirenaCarlos Arturo Torres-DuqueLaila SalamehPujan H PatelCharlotte Suppli UlrikEileen WangMichael E WechslerDavid J Pricenull nullPublished in: Allergy (2024)
Most patients with severe asthma are ineligible for RCTs of biologic therapies. Biologics are initiated in patients who have worse baseline impairments than non-initiators despite similar biomarker levels. Although biologic initiators exhibited clinical responses and super-responses in all outcome domains, 40-50% did not meet the response criteria.